Atrium Therapeutics Inc $RNA

Recent News (16)

• Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at Bradykinin Symposium 2026 PR Newswire · 04 Sep 2026 - Oral Presentation in Session VI: Hereditary Angioedema SHANGHAI and NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA …
• Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference GlobeNewswire · 03 Sep 2026 CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transf…
• Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines PR Newswire · 02 Sep 2026 – Typewriter's site-specific, non-viral technology uses only LNP-delivered RNA to insert whole genes into the genome, to create safer, re-dosable, durable genetic medicines – – Matthew Stanton, PhD, a…
• Atrium Therapeutics to Participate in Upcoming Investor Conferences PR Newswire · 02 Sep 2026 SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today…
• CAMP4 to Participate in Upcoming Investor Conferences GlobeNewswire · 01 Sep 2026 WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of reg…
• RNAV8 Bio Joins Team Selected for ARPA-H Funding to Develop Programmable RNA Medicines PR Newswire · 01 Sep 2026 Under an ARPA-H pilot award of up to $4.4 million over one year, the PROPEL program aims to control gene expression through RNA structure, building logic-gated RNA therapies that switch on only where …
• Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform? Yahoo Finance · 28 Aug 2026 Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
• CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene PR Newswire · 28 Aug 2026 Combines CREATE's multi-immune programming and RNA gene-writing platforms with WestGene's targeted LNP technology to support broad clinical proof of concept, including in China. Advances three next-ge…
• Korro to Participate in Upcoming Investor Conferences GlobeNewswire · 27 Aug 2026 CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform …
• Lexogen Expands NGS Services with GCLP-Compliant Workflows PR Newswire · 25 Aug 2026 VIENNA, Aug. 25, 2026 /PRNewswire/ -- Lexogen, a specialist in RNA sequencing technologies and next-generation sequencing services, announces the availability of designated NGS service workflows opera…
• Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics PR Newswire · 24 Aug 2026 SEONGNAM, South Korea, Aug. 23, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joinin…
• Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases PR Newswire · 19 Aug 2026 Research collaboration combines Amplitude's proprietary taRNA with Lilly's global development, manufacturing, and commercialization capabilities Initial programs target infectious diseases with high u…
• Atrium Therapeutics Reports Second Quarter 2026 Financial Results PR Newswire · 13 Aug 2026 -- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- …
• Mana.bio Announces the Appointment of Laura Sepp-Lorenzino to its Scientific Advisory Board PR Newswire · 27 Jul 2026 TEL AVIV, Israel and BOSTON, July 27, 2026 /PRNewswire/ -- Mana.bio, a biotechnology company revolutionizing targeted RNA delivery through AI-enabled lipid nanoparticle (LNP) discovery and optimizatio…
• FAST Awards Grant to Nobel Laureate Frances Arnold to Advance Next-Generation Tools for a Novel Therapeutic Strategy for Angelman Syndrome PR Newswire · 20 Jul 2026 FAST-funded project will apply directed evolution to develop new nucleoside analogs for RNA targeted technology designed to build on the progress already underway in Angelman syndrome research AUSTIN,…
• CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · 17 Jul 2026 CAMBRIDGE, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regu…